ArticleIJU case reports2026
PTHrP-Producing Renal Cell Carcinoma Presenting as Rapidly Progressive Cognitive Impairment: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Editorial Comments on PTHrP-Producing Renal Cell Carcinoma Presenting as Rapidly Progressive Cognitive Impairment: A Case Report.IJU case reports · 2026Article
- PTHrP-Producing Renal Cell Carcinoma Presenting as Rapidly Progressive Cognitive Impairment: A Case Report.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Humoral hypercalcemia of malignancy (HCM) caused by parathyroid hormone-related peptide (PTHrP) is a common paraneoplastic syndrome, and renal cell carcinoma (RCC) is one of the main causes. However, initial presentation with rapidly progressive cognitive decline is rare. Case Presentation: A 68-year-old woman was presented with a rapidly progressive cognitive impairment. Laboratory tests revealed severe hypercalcemia with elevated PTHrP and suppressed parathyroid hormone levels. Thoracoabdominal computed tomography revealed an 8-cm left renal mass, which was pathologically diagnosed as a sarcomatoid RCC. She underwent left radical nephrectomy, after which serum calcium normalized and cognitive function improved markedly (Hasegawa Dementia Scale-Revised score 7→28). Conclusion: This case demonstrates that an unexplained cognitive decline may be the first sign of PTHrP-producing RCC. Checking serum calcium levels is essential, and surgical removal of the tumor can reverse both metabolic and neurological symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.